-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Influenza-A-virus-IN-7
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2464415-40-3.gif)
| Category | Influenza Virus |
| CAS | 2464415-40-3 |
| Description | Influenza A virus-IN-7 (compound 16r) is a potent and orally active influenza A virus inhibitor with an IC50 of 3.43 µM and 50 of >100 µM. Influenza A virus-IN-7 shows anti-IAV activity with low cytotoxicity. Influenza A virus-IN-7 inhibits the transcription and replication of viral RNA |
Product Information
| Synonyms | Influenza A virus-IN-7|CHEMBL4776870|HY-146361|CS-0498475 |
| Molecular Weight | 459.54 |
| Molecular Formula | C29H25N5O |
| Canonical SMILES | C1CN(CC2=CC=CC=C21)C3=NC4=CC=CC=C4C(=N3)NCC(=O)NC5=CC6=CC=CC=C6C=C5 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 717 |
| Exact Mass | 459.20591044 |
| In Vivo | Influenza A virus-IN-7 (compound 16r) (1.25 mg/kg for i.v.; 25 mg/kg for p.o.) shows good PK profiles with oral bioavailability of 22.5%. |
| Target | IC50: 3.43 µM (influenza virus); CC50: >100 µM (influenza virus) |
| XLogP3-AA | 6 |
